Onconetix appoints Dr. Ajit Singh to board of directors

Onconetix, Inc., a commercial-stage biotechnology company focused on developing and commercializing therapeutics, diagnostics, and services for clinicians and patients in oncology, has appointed senior biotech executives Dr. Ajit Singh, and Dr. Thomas Meier, to its board of directors. Onconetix, Inc. has Entadfi, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology.

Another Alzheimer’s drug, made by Eli Lilly, shows promise to slow disease

Eli Lilly’s Alzheimer’s drug has shown promise to slow down cognitive and functional decline in people who are in early stages of the disease’s progression, according to results of phase 3 trial. This comes on the heels of Eisai and Biogen’s lecanemab, known by the brand name Leqembi, becoming the first to get US Food and Drug Administration’s (FDA) full approval, earlier this month, to slow down disease progression in adult patients with Alzheimer’s disease.